SNF Platform Study of HR+/ HER2-advanced Breast Cancer

The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

Trial Details

NCT ID
NCT05594095
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • PIK3CA inhibitor
  • AKT inhibitor
  • Carrelizumab
  • Famitinib
  • Fluzoparib
  • Dalpiciclib
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Female aged ≥18 years;
  • HR+/HER2- invasive breast cancer confirmed by histology (specific definition: ER \>10% positive tumor cells by immunohistochemistry is defined as E…
  • Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer;
  • HR+/HER2- advanced breast cancer patients who had previously received CDK4/6 inhibitor therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →